Cargando…

Inherited Variants in BLM and the Risk and Clinical Characteristics of Breast Cancer

Bloom Syndrome is a rare recessive disease which includes a susceptibility to various cancers. It is caused by homozygous mutations of the BLM gene. To investigate whether heterozygous carriers of a BLM mutation are predisposed to breast cancer, we sequenced BLM in 617 patients from Polish families...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kluźniak, Wojciech, Wokołorczyk, Dominika, Rusak, Bogna, Huzarski, Tomasz, Kashyap, Aniruddh, Stempa, Klaudia, Rudnicka, Helena, Jakubowska, Anna, Szwiec, Marek, Morawska, Sylwia, Gliniewicz, Katarzyna, Mordak, Karina, Stawicka, Małgorzata, Jarkiewicz-Tretyn, Joanna, Cechowska, Magdalena, Domagała, Paweł, Dębniak, Tadeusz, Lener, Marcin, Gronwald, Jacek, Lubiński, Jan, Narod, Steven A., Akbari, Mohammad R., Cybulski, Cezary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826355/ https://www.ncbi.nlm.nih.gov/pubmed/31614901 http://dx.doi.org/10.3390/cancers11101548

Ejemplares similares

Inherited variants in XRCC2 and the risk of breast cancer
por: Kluźniak, Wojciech, et al.
Publicado: (2019)

The APOBEC3B c.783delG Truncating Mutation Is Not Associated with an Increased Risk of Breast Cancer in the Polish Population
por: Gliniewicz, Katarzyna, et al.
Publicado: (2023)

Do BARD1 Mutations Confer an Elevated Risk of Prostate Cancer?
por: Stempa, Klaudia, et al.
Publicado: (2021)

Inherited NBN Mutations and Prostate Cancer Risk and Survival
por: Rusak, Bogna, et al.
Publicado: (2019)

Genetic predisposition to male breast cancer in Poland
por: Szwiec, Marek, et al.
Publicado: (2021)

BARD1 is a Low/Moderate Breast Cancer Risk Gene: Evidence Based on an Association Study of the Central European p.Q564X Recurrent Mutation
por: Suszynska, Malwina, et al.
Publicado: (2019)

Prevalence of Recurrent Mutations Predisposing to Breast Cancer in Early-Onset Breast Cancer Patients from Poland
por: Rogoża-Janiszewska, Emilia, et al.
Publicado: (2020)

Genetic testing for hereditary breast cancer in Poland: 1998–2022
por: Gronwald, Jacek, et al.
Publicado: (2023)

The Prevalence of Founder Mutations among Individuals from Families with Familial Pancreatic Cancer Syndrome
por: Lener, Marcin R., et al.
Publicado: (2017)

The risk of breast cancer in women with a CHEK2 mutation
por: Cybulski, Cezary, et al.
Publicado: (2012)

CHEK2 mutations as markers for high risk of breast cancer
por: Cybulski, Cezary, et al.
Publicado: (2012)

Risk of Second Primary Thyroid Cancer in Women with Breast Cancer
por: Cieszyńska, Monika, et al.
Publicado: (2022)

Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer
por: Łukomska, Alicja, et al.
Publicado: (2021)

Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband
por: Gronwald, J, et al.
Publicado: (2009)

Meeting abstracts from the Annual Conference on Hereditary Cancers 2016: Szczecin, Poland. 14-15 September 2016
por: Cybulski, C., et al.
Publicado: (2017)

Serum Selenium Level Predicts 10-Year Survival after Breast Cancer
por: Szwiec, Marek, et al.
Publicado: (2021)

Prevalence of germline TP53 variants among early-onset breast cancer patients from Polish population
por: Rogoża-Janiszewska, Emilia, et al.
Publicado: (2020)

NBS1 Mutation and prognosis of prostate cancer
por: Wokołorczyk, Dominika, et al.
Publicado: (2012)

Prostate cancer screening based on genotyping for high risk founder alleles
por: Cybulski, Cezary, et al.
Publicado: (2012)

HOXB13 mutations and prostate cancer in Poland
por: Kluźniak, Wojciech, et al.
Publicado: (2012)

The HOXB13 p.Gly84Glu mutation is not associated with the risk of breast cancer
por: Akbari, Mohammad R., et al.
Publicado: (2012)

Association of recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 with the risk of borderline ovarian tumor
por: Ogrodniczak, Alicja, et al.
Publicado: (2022)

Impact of BRCA1 mutation on survival after early onset breast cancer
por: Huzarski, T, et al.
Publicado: (2012)

Frequency of BRCA1 and BRCA2 mutations in ovarian cancer patients in South-East Poland
por: Jasiewicz, Andrzej, et al.
Publicado: (2022)

Why choose the treatment with cisplatin for BRCA1 breast cancers patients?
por: Byrski, T, et al.
Publicado: (2012)

Serum Essential Elements and Survival after Cancer Diagnosis
por: Lubiński, Jan, et al.
Publicado: (2023)

Selenium and the risk of cancer in BRCA1 carriers
por: Lubinski, J, et al.
Publicado: (2011)

Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
por: Byrski, T, et al.
Publicado: (2011)

BRCA1 founder mutations compared to ovarian cancer in Belarus
por: Savanevich, Alena, et al.
Publicado: (2014)

BRCA1/2 mutations are not a common cause of malignant melanoma in the Polish population
por: Dębniak, Tadeusz, et al.
Publicado: (2018)

Blood Copper Levels and the Occurrence of Colorectal Cancer in Poland
por: Baszuk, Piotr, et al.
Publicado: (2021)

A personalised approach to prostate cancer screening based on genotyping of risk founder alleles
por: Cybulski, C, et al.
Publicado: (2013)

Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA
por: Szczepanek, Joanna, et al.
Publicado: (2023)

Screening with Magnetic Resonance Imaging in women at low and intermediate risk of breast Cancer
por: Huzarski, T T, et al.
Publicado: (2012)

Serum selenium level and cancer risk: a nested case-control study
por: Narod, Steven A., et al.
Publicado: (2019)

An inherited NBN mutation is associated with poor prognosis prostate cancer
por: Cybulski, C, et al.
Publicado: (2013)

Blood arsenic levels and the risk of familial breast cancer in Poland
por: Marciniak, Wojciech, et al.
Publicado: (2019)

Screening with magnetic resonance imaging, mammography and ultrasound in women at average and intermediate risk of breast cancer
por: Huzarski, Tomasz, et al.
Publicado: (2017)

Prospective observation of breast/ovarian cancer risk in BRCA1 carriers depending on serum selenium level optimized with diet
por: Lubiński, J, et al.
Publicado: (2012)

Serum Selenium Level and 10-Year Survival after Melanoma
por: Rogoża-Janiszewska, Emilia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6s6chq7g4hl9a6rd9a9eduh8i2